Pathogenic role of mitochondrial amyloid-β peptide

References

• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol.82(4), 239–259 (1991).
   PubMed Web of Science ®Google Scholar
• Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41(4), 479–486 (1991).
   PubMed Web of Science ®Google Scholar
• Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature349(6311), 704–706 (1991).
   PubMed Web of Science ®Google Scholar
• Group AsDC. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat. Genet.11(2), 219–222 (1995).
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science269(5226), 973–977 (1995).
   PubMed Web of Science ®Google Scholar
• De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron38(1), 9–12 (2003).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA90(5), 1977–1981 (1993).
   PubMed Web of Science ®Google Scholar
• Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science274(5284), 99–102 (1996).
   PubMed Web of Science ®Google Scholar
• Mucke L, Masliah E, Yu GQ et al. High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci.20(11), 4050–4058 (2000).
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun.120(3), 885–890 (1984).
   PubMed Web of Science ®Google Scholar
• Hartmann T, Bieger SC, Bruhl B et al. Distinct sites of intracellular production for Alzheimer’s disease Aβ40/42 amyloid peptides. Nat. Med.3(9), 1016–1020 (1997).
   PubMed Web of Science ®Google Scholar
• Cook DG, Forman MS, Sung JC et al. Alzheimer’s Aβ1–42 is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med.3(9), 1021–1023 (1997).
   PubMed Web of Science ®Google Scholar
• Greenfield JP, Tsai J, Gouras GK et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc. Natl Acad. Sci. USA96(2), 742–747 (1999).
   PubMed Web of Science ®Google Scholar
• El Khoury J, Hickman SE, Thomas CA et al. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature382(6593), 716–719 (1996).
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature382(6593), 685–691 (1996).
   PubMed Web of Science ®Google Scholar
• Wertkin AM, Turner RS, Pleasure SJ et al. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular β-amyloid or A4 peptides. Proc. Natl Acad. Sci. USA90(20), 9513–9517 (1993).
   PubMed Web of Science ®Google Scholar
• Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S. Aβ42-positive non-pyramidal neurons around amyloid plaques in Alzheimer’s disease. Lancet355(9197), 42–43 (2000).
   PubMed Web of Science ®Google Scholar
• Nagele RG, D’Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience110(2), 199–211 (2002).
   PubMed Web of Science ®Google Scholar
• D’Andrea MR, Nagele RG, Wang HY, Lee DH. Consistent immunohistochemical detection of intracellular β-amyloid42 in pyramidal neurons of Alzheimer’s disease entorhinal cortex. Neuroscience Lett.333(3), 163–166 (2002).
   PubMed Web of Science ®Google Scholar
• Bancher C, Grundke-Iqbal I, Iqbal K, Kim KS, Wisniewski HM. Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to the amyloid-β protein. Neurobiol. Aging10(2), 125–132 (1989).
   PubMed Web of Science ®Google Scholar
• Takahashi RH, Milner TA, Li F et al. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol.161(5), 1869–1879 (2002).
   PubMed Web of Science ®Google Scholar
• Allsop D, Haga S, Bruton C, Ishii T, Roberts GW. Neurofibrillary tangles in some cases of dementia pugilistica share antigens with amyloid β-protein of Alzheimer’s disease. Am. J. Pathol.136(2), 255–260 (1990).
   PubMed Web of Science ®Google Scholar
• Wegiel J, Kuchna I, Nowicki K et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol.113(4), 389–402 (2007).
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci.8(7), 499–509 (2007).
   PubMed Web of Science ®Google Scholar
• Caspersen C, Wang N, Yao J et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J.19(14), 2040–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Sciaky N, Presley J, Smith C et al. Golgi tubule traffic and the effects of brefeldin A visualized in living cells. J. Cell Biol.139(5), 1137–1155 (1997).
   PubMed Web of Science ®Google Scholar
• Caporaso GL, Takei K, Gandy SE et al. Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer β/A4 amyloid precursor protein. J. Neurosci.14(5 Pt 2), 3122–3138 (1994).
   PubMed Web of Science ®Google Scholar
• Manczak M, Anekonda TS, Henson E et al. Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet.15(9), 1437–1449 (2006).
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Blake R, Duce JA et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-β1–42. J. Neurosci.25(3), 672–679 (2005).
   PubMed Web of Science ®Google Scholar
• Langui D, Girardot N, El Hachimi KH et al. Subcellular topography of neuronal Aβ peptide in APPxPS1 transgenic mice. Am. J. Clin. Pathol.165(5), 1465–1477 (2004).
   Google Scholar
• Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol.161(1), 41–54 (2003).
   PubMed Web of Science ®Google Scholar
• Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J. Neurosci.26(35), 9057–9068 (2006).
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SS, Seong YM et al. β-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J. Biol. Chem.281(45), 34277–34287 (2006).
   PubMed Web of Science ®Google Scholar
• Hansson CA, Frykman S, Farmery MR et al. Nicastrin, presenilin, APH-1, and PEN-2 form active γ-secretase complexes in mitochondria. J. Biol. Chem.279(49), 51654–51660 (2004).
   PubMed Web of Science ®Google Scholar
• Vetrivel KS, Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurology66(2 Suppl. 1), S69–S73 (2006).
   PubMed Web of Science ®Google Scholar
• Lustbader JW, Cirilli M, Lin C et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer’s disease. Science304(5669), 448–452 (2004).
   PubMed Web of Science ®Google Scholar
• Lawson CA, Yan SD, Yan SF et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J. Clin. Invest.99(7), 1729–1738 (1997).
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Lustbader J, Arancio O, Wu H. ABAD: mitochondrial target for amyloid-induced cellular perturbation relevant to Alzheimer disease. In: Research Progress in Alzheimer Disease and Dementia. Sun M-K (Ed.). Nova Science Publishers, Inc., NY, USA 175–189 (2006).
   Google Scholar
• Yan Y, Liu Y, Sorci M et al. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD–Aβ interaction. Biochemistry46(7), 1724–1731 (2007).
   PubMed Web of Science ®Google Scholar
• Yan SD, Fu J, Soto C et al. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer’s disease. Nature389(6652), 689–695 (1997).
   PubMed Web of Science ®Google Scholar
• Takuma K, Yao J, Huang J et al. ABAD enhances Aβ-induced cell stress via mitochondrial dysfunction. FASEB J.19(6), 597–598 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science285(5433), 1569–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Aarts M, Liu Y, Liu L et al. Treatment of ischemic brain damage by perturbing NMDA receptor–PSD-95 protein interactions. Science298(5594), 846–850 (2002).
   PubMed Web of Science ®Google Scholar
• Silverman DH, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA286(17), 2120–2127 (2001).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Herholz K, Prohovnik I et al. Metabolic interaction between ApoE genotype and onset age in Alzheimer’s disease: implications for brain reserve. J. Neurol. Neurosurg. Psychiatr.76(1), 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Nacmias B, Sorbi S et al. Brain metabolic decreases related to the dose of the ApoE ε4 allele in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr.75(3), 370–376 (2004).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Sorbi S, Nacmias B et al. Age and ApoE genotype interaction in Alzheimer’s disease: an FDG-PET study. Psychiatry Res.130(2), 141–151 (2004).
   PubMed Web of Science ®Google Scholar
• Hirai K, Aliev G, Nunomura A et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci.21(9), 3017–3023 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Perry G, Moreira PI et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis.9(2), 147–153 (2006).
   PubMed Web of Science ®Google Scholar
• Moreira PI, Santos MS, Seica R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetes. J. Neurol. Sci.257(1–2), 206–214 (2007).
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenzyme A-acetylating enzymes in Alzheimer’s disease: possible cholinergic ‘compartment’ of pyruvate dehydrogenase. Neurosci. Lett.18(1), 105–110 (1980).
   PubMed Web of Science ®Google Scholar
• Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol.13(1), 72–78 (1983).
   PubMed Web of Science ®Google Scholar
• Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer’s disease. Metab. Brain Dis.5(4), 179–184 (1990).
   PubMed Web of Science ®Google Scholar
• Krugel U, Bigl V, Eschrich K, Bigl M. Deafferentation of the septo–hippocampal pathway in rats as a model of the metabolic events in Alzheimer’s disease. Int. J. Dev. Neurosci.19(3), 263–277 (2001).
   PubMed Web of Science ®Google Scholar
• Gibson GE, Haroutunian V, Zhang H et al. Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype. Ann. Neurol.48(3), 297–303 (2000).
   PubMed Web of Science ®Google Scholar
• Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm.105(8–9), 855–870 (1998).
   PubMed Web of Science ®Google Scholar
• Gibson GE, Zhang H, Sheu KF et al. α-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Ann. Neurol.44(4), 676–681 (1998).
   PubMed Web of Science ®Google Scholar
• Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol.57(5), 695–703 (2005).
   PubMed Web of Science ®Google Scholar
• Parker WD Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology40(8), 1302–1303 (1990).
   PubMed Web of Science ®Google Scholar
• Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer’s disease brain. Neurology44(6), 1090–1096 (1994).
   PubMed Web of Science ®Google Scholar
• Parker WD Jr, Parks JK. Cytochrome c oxidase in Alzheimer’s disease brain: purification and characterization. Neurology45(3 Pt 1), 482–486 (1995).
   PubMed Web of Science ®Google Scholar
• Kish SJ, Bergeron C, Rajput A et al. Brain cytochrome oxidase in Alzheimer’s disease. J. Neurochem.59(2), 776–779 (1992).
   PubMed Web of Science ®Google Scholar
• Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer’s patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci.21(13), 4923–4930 (2001).
   PubMed Web of Science ®Google Scholar
• Cardoso SM, Santos S, Swerdlow RH, Oliveira CR. Functional mitochondria are required for amyloid β-mediated neurotoxicity. FASEB J.15(8), 1439–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Aβ toxicity. J. Neurochem.89(6), 1417–1426 (2004).
   PubMed Web of Science ®Google Scholar
• Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. β-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem.80(1), 91–100 (2002).
   PubMed Web of Science ®Google Scholar
• Torroja L, Ortuno-Sahagun D, Ferrus A, Hammerle B, Barbas JA. scully, an essential gene of Drosophila, is homologous to mammalian mitochondrial type II L-3-hydroxyacyl-CoA dehydrogenase/amyloid-β peptide-binding protein. J. Cell Biol.141(4), 1009–1017 (1998).
   PubMed Web of Science ®Google Scholar
• Gibson KM, Burlingame TG, Hogema B et al. 2-methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. Pediatr. Res.47(6), 830–833 (2000).
   Google Scholar
• Olpin SE, Pollitt RJ, McMenamin J et al. 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency in a 23-year-old man. J. Inherit. Metab. Dis.25(6), 477–482 (2002).
   PubMed Web of Science ®Google Scholar
• Sutton VR, O’Brien WE, Clark GD, Kim J, Wanders RJ. 3-hydroxy-2-methylbutyryl-CoA dehydrogenase deficiency. J. Inherit. Metab. Dis.26(1), 69–71 (2003).
   PubMed Web of Science ®Google Scholar
• Zschocke J, Ruiter JP, Brand J et al. Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr. Res.48(6), 852–855 (2000).
   PubMed Web of Science ®Google Scholar
• Korman SH. Inborn errors of isoleucine degradation: a review. Mol. Genet. Metab.89(4), 289–299 (2006).
   PubMed Web of Science ®Google Scholar
• Burlina AB, Gibson KM, Ruitenbeek W, Bonafe L, Bennett MJ. Profound neurological phenotype in a patient presenting with disordered isoleucine and energy metabolism. J. Inherit. Metab. Dis.21(8), 864–866 (1998).
   PubMed Web of Science ®Google Scholar
• Ensenauer R, Niederhoff H, Ruiter JP et al. Clinical variability in 3-hydroxy-2-methylbutyryl-CoA dehydrogenase deficiency. Ann. Neurol.51(5), 656–659 (2002).
   PubMed Web of Science ®Google Scholar
• Lenski C, Kooy RF, Reyniers E et al. The reduced expression of the HADH2 protein causes X-linked mental retardation, choreoathetosis, and abnormal behavior. Am. J. Hum. Genet.80(2), 372–377 (2007).
   PubMed Web of Science ®Google Scholar
• Chen X, Yan SD. Mitochondrial Aβ: a potential cause of metabolic dysfunction in Alzheimer’s disease. IUBMB Life58(12), 686–694 (2006).
   PubMed Web of Science ®Google Scholar
• Kissinger CR, Rejto PA, Pelletier LA et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer’s disease therapeutics. J. Mol. Biol.342(3), 943–952 (2004).
   PubMed Web of Science ®Google Scholar
• Xie Y, Deng S, Chen Z, Yan S, Landry DW. Identification of small-molecule inhibitors of the Aβ–ABAD interaction. Bioorg. Med. Chem. Lett.16(17), 4657–4660 (2006).
   PubMed Web of Science ®Google Scholar